Aventis Pharmaceuticals Inc.

Sanofi

Sanofi-a Ventis Deutschland Gmbh

Stephen J Shimshock

Stephanie Hachtel

Juergen Dedio

Carolina Lanter

Raymond W Kosley, Jr

Armin Walser

Pavel Safar

Rosy Sher

Holger Heitsch

Aleksandra Weichsel

Sven Grueneberg

Josef Pernerstorfer

Werngard Czechtizky

Raymond Kosley

Hui Li

Elisabeth Defossa

John G Jurcak

Bruce M Baron

Patrick Jimonet

Marcel Patek

Mark G Palermo

Matthieu Barrague

Joseph Guiles

William Jerome Bock

Xu-Yang Zhao

Abdul Ezaz Mutlib

Paul Justin Mueller

Charlie Chen

Susan M Chesson

Veronica Wolf

Jennifer Beall

Chung-Yi Kung

Raymond W Kosley

Jr Raymond W Kosley

Joseph W Guiles

The invention relates to compounds of the formula I in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

CXCR2 inhibitors

CXCR2 antagonists

The invention relates to compounds of the formula I in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

Inhibitors of CXCR2

The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R, R, Rand X are as defined herein.

N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof

Sulfonamide and urea compounds having an inhibitory effect on Src kinase including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formula II are disclosed and claimed: 

Substituted sulfonamides and ureas useful for inhibiting kinase activity

Amide, sulfonamide and urea compounds having an inhibitory effect on Src kinase including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formulae I and II:

Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity

Novel aminoalkylphenols, intermediates and processes for the preparation thereof, and methods of relieving memory dysfunction utilizing the aminoalkylphenols or compositions thereof are disclosed.

Aminoalkylphenol derivatives and related compounds

This application relates to compounds of the formula ##STR1## wherein R, X and Y are defined within, which compounds are useful for the treatment of memory dysfunction characterized by decreased cholinergic function, and for analgesia, pharmaceutical compositions containing the compounds and methods for making and using the compounds.

Isatin derivatives as acetylcholinesterase inhibitors and analgesics

Growing community of inventors

Somerville, NJ, United States of America

Stephen J Shimshock